Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

FDA Approves FoundationOne Liquid CDx for Solid Tumors

August 27th 2020

The FDA has approved the FoundationOne Liquid CDx, a liquid biopsy for all solid tumors with multiple companion diagnostic indications.

Dr. Shum on Emerging Targeted Therapies in EGFR-Mutant NSCLC

August 25th 2020

Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.

Dr. Partridge on the Role of Genomic Testing in Breast Cancer

August 25th 2020

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.

FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC

August 25th 2020

The FDA has granted a priority review designation to new drug application for tepotinib as a treatment for patient with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation identified via an FDA-approved test.

Companion Diagnostic, Targeted Therapy Approvals Rise in Tandem

August 23rd 2020

As precision medicine evolves in oncology, companion diagnostics are broadly and increasingly being adopted to guide treatment decisions, enabling clinicians to better and more precisely direct patients to therapies that best suit their unique genomic profiles.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

August 20th 2020

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Presence of ctDNA, CTCs Independently Linked With Early-Stage TNBC Recurrence

August 19th 2020

A new, recently patented liquid biopsy device designed to detect small amounts of genetic and cellular material from tumors in the bloodstream of patients with early-stage, recurrent triple negative breast cancer, following neoadjuvant chemotherapy, has shown great accuracy and sensitivity.

Dr. Bunn on Targeting HER3 in NSCLC

August 18th 2020

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

Cell-Free DNA Analysis Could Aid in Detection, Optimal Management of Resistant Metastatic Prostate Cancer

August 18th 2020

Cell-free DNA–based androgen receptor locus alterations and enhancers correlated with metastatic prostate cancers determined to be resistant to AR-targeted therapies.

Dabrafenib Plus Trametinib Elicits Encouraging Responses in BRAF V600E-Mutant Tumors

August 13th 2020

The combination of dabrafenib and trametinib elicited favorable response rates in a mixed histology cohort of pretreated patients with solid tumors, lymphomas, and multiple myeloma whose tumors harbored a BRAF V600 mutation.

ADCs Are Poised to Enter HER2-Mutant NSCLC Armamentarium

August 10th 2020

Paul A. Bunn, Jr, MD, discusses antibody-drug conjugates and how they are on the cusp of being introduced into the treatment paradigm for patients with HER2-mutant non–small cell lung cancer.

FDA Approves Guardant360 CDx Liquid Biopsy for Comprehensive Genomic Profiling Across All Solid Cancers

August 7th 2020

The FDA has approved Guardant360® CDx for comprehensive genomic profiling in patients with any solid malignant cancer.

FDA Clears First MRD Assay for Chronic Lymphocytic Leukemia

August 6th 2020

The FDA has cleared the clonoSEQ® assay to identify and monitor minimal residual disease in blood or bone marrow from patients with chronic lymphocytic leukemia.

HRD Testing Heralds a New Biomarker, but Questions Linger

August 5th 2020

Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.

Entrectinib Approved in Europe for NTRK+ Tumors and ROS1+ NSCLC

August 3rd 2020

The European Commission has approved entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, as well as for the treatment of adult patients with ROS1-positive, advanced non—small cell lung cancer not previously treated with ROS1 inhibitors.

Genetic Counselor Addresses Common Questions About Testing in Oncology

August 1st 2020

Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types.

Long-Term Consequences for Cancer Detection Loom Amid COVID-19

July 30th 2020

The coronavirus disease 2019 has disrupted the global delivery of coordinated cancer care, resulting in declines in routine screening and referrals that could lead to thousands of excess deaths due to delayed diagnoses, experts warn.

Rare TP53 Mutation Confers Risk of Several Cancers in Ashkenazi Jewish Population

July 28th 2020

A lower-risk TP53 mutation has been linked with a specific kind of Li Fraumeni Syndrome which predisposes individuals to a wide range of cancers, and this newly described variant of p53 is most commonly found in the Ashkenazi Jewish population.

FDA Grants BDTX-189 Fast Track Status to Solid Tumors Harboring Select EGFR, HER2 Mutations

July 28th 2020

The FDA has granted a fast track designation to BDTX-189 for use in adult patients with solid tumors harboring an allosteric HER2 mutation or an EGFR or HER2 exon 20 insertion mutation who had progressed on previous treatment and have no acceptable options available.

ASCO and ACCC Collaborate to Boost Racial/Ethnic Representation in Cancer Treatment Trials

July 27th 2020

A new collaboration between the American Society of Clinical Oncology and the Association of Community Cancer Centers aims to encourage the enrollment of more racially and ethnically diverse patients with cancer onto clinical trials.